INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 424m ago
HOUSE PTR24m ago
SEC 13F24m ago
ROBINHOOD CHAIN24m ago
SEC FORM 4/Grant or awardVerified dataRule 10b5-1 plan

Rote William E. reported TVTX

Chief Research Officer · Travere Therapeutics, Inc. · Common Stock

Side
A
Value
—
Shares
14.0K
Price
—
Executed
Apr 13, 2026
Disclosed
Apr 15, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Apr 13 executedApr 15, 2026 disclosed

TVTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 12.8% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TVTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$1.79M
    200.0K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    11
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$4.31M
    78.4K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    0
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    200.0K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    0
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    43.7K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    11
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.02M
    37.3K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    5
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$1.18M
    43.7K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    11
    DM
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$6.78M
    128.1K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    21
    IJ
    Inrig JulaEVP, Head of R&D & CMO
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.08M
    17.3K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    7
    CS
    Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,250 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CS
    Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$33K
    1,625 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CS
    Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,625 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CR
    Cline Christopher R.CHIEF FINANCIAL OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    20.0K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    11
    CR
    Cline Christopher R.CHIEF FINANCIAL OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$121K
    1,900 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    21
    CR
    Cline Christopher R.CHIEF FINANCIAL OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.30M
    20.7K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    2
    CR
    Cline Christopher R.CHIEF FINANCIAL OFFICER
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$349K
    20.0K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    6
    IJ
    Inrig JulaEVP, Head of R&D & CMO
    TVTXTravere Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$289K
    32.4K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    14
    CS
    Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$50K
    800 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    11
    CS
    Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$19K
    300 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    21
    CR
    Cline Christopher R.CHIEF FINANCIAL OFFICER
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.70M
    27.5K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    8
    IJ
    Inrig JulaEVP, Head of R&D & CMO
    TVTXTravere Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$26K
    400 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001698262-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 13, 2026
    Published
    Apr 15, 2026
    Ingested by INSIDER
    Nov 5, 04:04 UTC
    Last re-read
    Nov 5, 04:04 UTC

    Extracted facts

    Filer
    Rote William E.
    Role
    Chief Research Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Travere Therapeutics, Inc.
    Ticker
    TVTX
    Shares
    14.0K
    Price per share
    $0
    Execution date (reported)
    Apr 13, 2026
    Owned after transaction
    123.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Rote William E. filed this Form 4 reporting a grant or award of TVTX on Apr 13, 2026. It became public on Apr 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Research Officer
    Rote William E.cik:0001698262
    Issuer
    Travere Therapeutics, Inc.cik:0001438533

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.